Show simple item record

dc.contributor.authorLenz, Kimberly J.
dc.contributor.authorThompson, Tyson
dc.date2022-08-11T08:08:07.000
dc.date.accessioned2022-08-23T15:43:08Z
dc.date.available2022-08-23T15:43:08Z
dc.date.issued2017-04-27
dc.date.submitted2017-06-28
dc.identifier.citation<p>Lenz KJ , Thompson T. Substance Use Disorder Privacy Law Limits Both Payers, Prescribers. Managed Healthcare Executive, April 27, 2017.</p>
dc.identifier.urihttp://hdl.handle.net/20.500.14038/27016
dc.description.abstractWe should reform or align 42 CFR Part 2 with HIPAA to better serve patients with substance use disorder, UMass Medical School pharmacists Kimberly Lenz and Tyson Thompson write in an opinion piece for Managed Healthcare Executive.
dc.language.isoen_US
dc.relation.urlhttps://www.managedhealthcareexecutive.com/managed-healthcare-executive/news/opinion-substance-use-disorder-privacy-law-limits-both-payers-prescribers
dc.subjectSubstance use disorder
dc.subjectprivacy
dc.subjectmanaged care
dc.subjectopioid management
dc.subjectHealth Policy
dc.subjectHealth Services Administration
dc.subjectSubstance Abuse and Addiction
dc.titleSubstance Use Disorder Privacy Law Limits Both Payers, Prescribers
dc.typeNews Article
dc.source.journaltitleManaged Healthcare Executive
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/commed_pubs/25
dc.identifier.contextkey10368119
html.description.abstract<p>We should reform or align 42 CFR Part 2 with HIPAA to better serve patients with substance use disorder, UMass Medical School pharmacists Kimberly Lenz and Tyson Thompson write in an opinion piece for Managed Healthcare Executive.</p>
dc.identifier.submissionpathcommed_pubs/25
dc.contributor.departmentClinical Pharmacy Services
dc.contributor.departmentCenter for Health Policy and Research
dc.contributor.departmentCommonwealth Medicine


This item appears in the following Collection(s)

Show simple item record